Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.53 |
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | HPN | P05981 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105025 | 0.79 | PIM1 (0.55) | OGAOPRD1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL20304724 | 0.78 | PIM1 (0.54) | OGAOPRD1ALDH1A1KMT2A | |
| SCHEMBL12076004 | 0.76 | PRKACA (0.41) | KMT2A | |
| Hydrochloric Acid SCHEMBL20304896 | 0.73 | PIM1 (0.49) | OGAOPRD1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL20304894 | 0.73 | PIM1 (0.49) | OGAOPRD1ALDH1A1KMT2A | |
| SCHEMBL30576754 | 0.72 | CES2 (0.35) | — | |
| SCHEMBL6431796 | 0.72 | SRD5A2 (0.49) | F2F10PARP10OGASRD5A2 | |
| SCHEMBL14730978 | 0.72 | MAOA (0.43) | KMT2A | |
| SCHEMBL16322736 | 0.72 | HTR2C (0.48) | — | |
| SCHEMBL20015685 | 0.72 | IKBKB (0.48) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829542-A | Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient | 韩国化学研究院 | 2023-09-29 | — | — | CN | disclosed |
| US-7049441-B2 | Process for preparation of benzylpiperidine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-23 | — | — | US | disclosed |
| US-20060094877-A1 | Process for preparation of benzylpiperidine compounds | MIKI SHOKYO | 2006-05-04 | — | — | US | disclosed |
| US-20050038257-A1 | Process for preparation of benzylpiperidine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-17 | — | — | US | disclosed |
| US-6833457-B1 | Process for preparation of benzylpiperidine compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-21 | — | — | US | disclosed |
| EP-1359145-A1 | PROCESS FOR PREPARATION OF BENZYLPIPERIDINE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038257-A1 | Process for preparation of benzylpiperidine compounds | SBDS, DRD4, HRH1 | F2 708/4885F10 2593/4885PARP10 262/4885 |
| US-20060094877-A1 | Process for preparation of benzylpiperidine compounds | SBDS, DRD4, HRH1 | F2 708/4885F10 2593/4885PARP10 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.